SANTA CLARA, Calif., June 1, 2026
Agilent Technologies and Sound Analytics have announced a strategic collaboration aimed at transforming liquid chromatography–mass spectrometry (LC/MS) workflows for drug metabolism and pharmacokinetics (DMPK) research, an essential component of modern pharmaceutical and biopharmaceutical drug development. The partnership brings together Agilent’s industry-leading 1290 Infinity III Liquid Chromatography system and 6495D Triple Quadrupole Mass Spectrometer with Sound Analytics’ LeadScape™ for Agilent software, creating an integrated analytical workflow designed to enhance efficiency, improve data quality, and streamline laboratory operations. As pharmaceutical companies face growing pressure to accelerate drug discovery timelines while maintaining rigorous scientific standards, the collaboration seeks to provide researchers with a comprehensive solution capable of delivering reliable, high-quality analytical data across a wide range of drug metabolism applications. The initiative reflects the increasing importance of advanced analytical technologies in supporting next-generation pharmaceutical innovation and accelerating the path from early-stage discovery to clinical development.
Integrated LC/MS Workflow Designed for Faster Drug Development
Drug metabolism and pharmacokinetics laboratories play a critical role in determining how experimental compounds are absorbed, distributed, metabolized, and eliminated within biological systems. These studies generate crucial data that influence drug candidate selection, dosing strategies, safety evaluations, and regulatory decision-making. Through this collaboration, Agilent and Sound Analytics aim to simplify and optimize these complex workflows by integrating high-performance analytical instrumentation with intelligent workflow software. The combined solution allows researchers to utilize Agilent’s advanced chromatography and mass spectrometry platforms alongside LeadScape software to support both routine and high-throughput DMPK analysis.
By reducing workflow complexity and improving laboratory efficiency, the integrated system helps scientists generate robust analytical results while minimizing operational bottlenecks. The collaboration addresses a growing industry need for solutions capable of balancing speed, sensitivity, robustness, and operational simplicity, particularly as pharmaceutical pipelines continue to expand and research organizations seek faster development cycles.
Advanced Technology Supports High-Quality Analytical Data
Advertisement
At the heart of the collaboration is a focus on delivering superior analytical performance while maintaining ease of implementation within existing laboratory environments. Agilent’s 1290 Infinity III LC system is widely recognized for its precision, reproducibility, and high-throughput capabilities, while the 6495D Triple Quadrupole Mass Spectrometer offers exceptional sensitivity and quantitative accuracy for complex biological samples. Combined with Sound Analytics’ LeadScape workflow software, researchers gain access to enhanced data management capabilities, workflow optimization tools, and streamlined sample analysis processes.
The integrated platform is specifically designed to support DMPK scientists tasked with processing large volumes of samples while maintaining confidence in data integrity and reproducibility. As pharmaceutical companies increasingly rely on sophisticated analytical technologies to identify promising drug candidates and evaluate therapeutic performance, integrated LC/MS solutions are becoming essential components of modern drug discovery infrastructure. The collaboration demonstrates how advanced instrumentation and intelligent software can work together to improve scientific productivity and support more informed research decisions.
Manageable Safety Profile Supports Global Development Plans
The partnership between Agilent and Sound Analytics reflects broader trends within the pharmaceutical industry, where automation, workflow integration, and digital transformation are reshaping laboratory operations. Biopharmaceutical companies, pharmaceutical manufacturers, and contract research organizations continue to seek technologies that reduce manual processes, improve scalability, and accelerate research timelines without compromising data quality. By combining trusted analytical instrumentation with specialized workflow software, the new solution aims to lower adoption barriers for laboratories seeking to modernize their DMPK operations.
Industry experts view integrated analytical ecosystems as a key driver of future pharmaceutical innovation, enabling researchers to generate actionable insights more rapidly and efficiently. As demand for precision medicines, biologics, and complex therapeutic modalities continues to grow, robust DMPK workflows will remain essential to successful drug development programs. Through this collaboration, Agilent and Sound Analytics are helping establish a new benchmark for workflow-focused analytical solutions that support the evolving needs of pharmaceutical research and contribute to the advancement of next-generation therapeutics.
Source: Agilent Technologies, Sound Analytics press release
